Detection of clinically suspected prostate cancer using ultrasound-guided transrectal biopsy is standard of care [1].
The relatively high probability of missing clinically significant cancers during initial sextant biopsies led to the introduction of extended 10-12 core biopsy and subsequently to 20+ core saturation biopsy strategies [1-9]. Nevertheless, underdiagnosis of high risk prostate cancer even in patients with low PSA levels still occurs in 25-30% [10,11]. Anteriorly located prostate cancer contributes to these high rates and data from magnetic resonance imaging (MRI) studies underlines these considerations [12-14].
Written by:
Seles M, Gutschi T, Mayrhofer K, Fischereder K, Ehrlich G, Gallé G, Gutschi S, Pachernegg O, Pummer K, Augustin H. Are you the author?
Department of Urology, Medical University of Graz, Austria.
Reference: BJU Int. 2015 Feb 26. Epub ahead of print.
doi: 10.1111/bju.13108
PubMed Abstract
PMID: 25726856